Mirvetuximab soravtansine (IMGN853), an ADC, is a potential new treatment for patients with folate receptor alpha (FRα)-positive cancer. These include many ovarian cancers, as well as other types of solid tumors (e.g., endometrial).

Mirvetuximab soravtansine is ImmunoGen’s lead program and is in clinical testing in the Phase 3 FORWARD I trial as a single agent for the treatment of platinum-resistant ovarian cancer. The candidate is also being assessed in combination regimens for both platinum-resistant and platinum-sensitive disease in the Phase 1b/2 FORWARD II trial.

For more information, visit www.clinicaltrials.gov.

The US Food and Drug Administration granted orphan drug designation to mirvetuximab soravtansine for the treatment of ovarian cancer; mirvetuximab soravtansine has also received this designation in the EU.

ASCO 2017 Poster Presentations